Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 137

1.

Understanding the tumor immune microenvironment (TIME) for effective therapy.

Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, Coussens LM, Gabrilovich DI, Ostrand-Rosenberg S, Hedrick CC, Vonderheide RH, Pittet MJ, Jain RK, Zou W, Howcroft TK, Woodhouse EC, Weinberg RA, Krummel MF.

Nat Med. 2018 May;24(5):541-550. doi: 10.1038/s41591-018-0014-x. Epub 2018 Apr 23. Review.

PMID:
29686425
2.

Myeloid derived-suppressor cells: their role in cancer and obesity.

Ostrand-Rosenberg S.

Curr Opin Immunol. 2018 Apr;51:68-75. doi: 10.1016/j.coi.2018.03.007. Epub 2018 Mar 13. Review.

PMID:
29544121
3.

Frontline Science: High fat diet and leptin promote tumor progression by inducing myeloid-derived suppressor cells.

Clements VK, Long T, Long R, Figley C, Smith DMC, Ostrand-Rosenberg S.

J Leukoc Biol. 2018 Mar;103(3):395-407. doi: 10.1002/JLB.4HI0517-210R. Epub 2018 Jan 3.

PMID:
29345342
4.

Myeloid-Derived Suppressor Cells: Immune-Suppressive Cells That Impair Antitumor Immunity and Are Sculpted by Their Environment.

Ostrand-Rosenberg S, Fenselau C.

J Immunol. 2018 Jan 15;200(2):422-431. doi: 10.4049/jimmunol.1701019. Review.

PMID:
29311384
5.

Differential Content of Proteins, mRNAs, and miRNAs Suggests that MDSC and Their Exosomes May Mediate Distinct Immune Suppressive Functions.

Geis-Asteggiante L, Belew AT, Clements VK, Edwards NJ, Ostrand-Rosenberg S, El-Sayed NM, Fenselau C.

J Proteome Res. 2018 Jan 5;17(1):486-498. doi: 10.1021/acs.jproteome.7b00646. Epub 2017 Nov 27.

PMID:
29139296
6.

Soluble CD80 Protein Delays Tumor Growth and Promotes Tumor-Infiltrating Lymphocytes.

Horn LA, Long TM, Atkinson R, Clements V, Ostrand-Rosenberg S.

Cancer Immunol Res. 2018 Jan;6(1):59-68. doi: 10.1158/2326-6066.CIR-17-0026. Epub 2017 Nov 9.

PMID:
29122838
7.

Ubiquitin Conjugation Probed by Inflammation in Myeloid-Derived Suppressor Cell Extracellular Vesicles.

Adams KR, Chauhan S, Patel DB, Clements VK, Wang Y, Jay SM, Edwards NJ, Ostrand-Rosenberg S, Fenselau C.

J Proteome Res. 2018 Jan 5;17(1):315-324. doi: 10.1021/acs.jproteome.7b00585. Epub 2017 Nov 10.

PMID:
29061044
8.

CD3xPDL1 bi-specific T cell engager (BiTE) simultaneously activates T cells and NKT cells, kills PDL1+ tumor cells, and extends the survival of tumor-bearing humanized mice.

Horn LA, Ciavattone NG, Atkinson R, Woldergerima N, Wolf J, Clements VK, Sinha P, Poudel M, Ostrand-Rosenberg S.

Oncotarget. 2017 Aug 3;8(35):57964-57980. doi: 10.18632/oncotarget.19865. eCollection 2017 Aug 29.

9.

Professor Enrico Mihich, 1928-2016.

Pawelec G, Ostrand-Rosenberg S.

Cancer Immunol Immunother. 2017 Jul;66(7):955-957. doi: 10.1007/s00262-017-2024-9. Epub 2017 May 29. No abstract available.

PMID:
28555257
10.

Frontline Science: Myeloid-derived suppressor cells (MDSCs) facilitate maternal-fetal tolerance in mice.

Ostrand-Rosenberg S, Sinha P, Figley C, Long R, Park D, Carter D, Clements VK.

J Leukoc Biol. 2017 May;101(5):1091-1101. doi: 10.1189/jlb.1HI1016-306RR. Epub 2016 Dec 22.

11.

Tumor-induced MDSC act via remote control to inhibit L-selectin-dependent adaptive immunity in lymph nodes.

Ku AW, Muhitch JB, Powers CA, Diehl M, Kim M, Fisher DT, Sharda AP, Clements VK, O'Loughlin K, Minderman H, Messmer MN, Ma J, Skitzki JJ, Steeber DA, Walcheck B, Ostrand-Rosenberg S, Abrams SI, Evans SS.

Elife. 2016 Dec 8;5. pii: e17375. doi: 10.7554/eLife.17375.

12.

Evaluation of Spectral Counting for Relative Quantitation of Proteoforms in Top-Down Proteomics.

Geis-Asteggiante L, Ostrand-Rosenberg S, Fenselau C, Edwards NJ.

Anal Chem. 2016 Nov 15;88(22):10900-10907. Epub 2016 Oct 31.

PMID:
27748581
13.

Surface Glycoproteins of Exosomes Shed by Myeloid-Derived Suppressor Cells Contribute to Function.

Chauhan S, Danielson S, Clements V, Edwards N, Ostrand-Rosenberg S, Fenselau C.

J Proteome Res. 2017 Jan 6;16(1):238-246. doi: 10.1021/acs.jproteome.6b00811. Epub 2016 Oct 20.

PMID:
27728760
14.

Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards.

Bronte V, Brandau S, Chen SH, Colombo MP, Frey AB, Greten TF, Mandruzzato S, Murray PJ, Ochoa A, Ostrand-Rosenberg S, Rodriguez PC, Sica A, Umansky V, Vonderheide RH, Gabrilovich DI.

Nat Commun. 2016 Jul 6;7:12150. doi: 10.1038/ncomms12150. Review.

15.

Peptide-based systems analysis of inflammation induced myeloid-derived suppressor cells reveals diverse signaling pathways.

Choksawangkarn W, Graham LM, Burke M, Lee SB, Ostrand-Rosenberg S, Fenselau C, Edwards NJ.

Proteomics. 2016 Jul;16(13):1881-8. doi: 10.1002/pmic.201500102.

PMID:
27193397
16.

Myeloid-Derived Suppressor Cell Survival and Function Are Regulated by the Transcription Factor Nrf2.

Beury DW, Carter KA, Nelson C, Sinha P, Hanson E, Nyandjo M, Fitzgerald PJ, Majeed A, Wali N, Ostrand-Rosenberg S.

J Immunol. 2016 Apr 15;196(8):3470-8. doi: 10.4049/jimmunol.1501785. Epub 2016 Mar 2.

17.

High-mobility group box protein 1 promotes the survival of myeloid-derived suppressor cells by inducing autophagy.

Parker KH, Horn LA, Ostrand-Rosenberg S.

J Leukoc Biol. 2016 Sep;100(3):463-70. doi: 10.1189/jlb.3HI0715-305R. Epub 2016 Feb 10.

18.

Tolerance and immune suppression in the tumor microenvironment.

Ostrand-Rosenberg S.

Cell Immunol. 2016 Jan;299:23-9. doi: 10.1016/j.cellimm.2015.09.011. Epub 2015 Sep 30.

19.

Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment.

Parker KH, Beury DW, Ostrand-Rosenberg S.

Adv Cancer Res. 2015;128:95-139. doi: 10.1016/bs.acr.2015.04.002. Epub 2015 May 12. Review.

20.

Top-down analysis of low mass proteins in exosomes shed by murine myeloid-derived suppressor cells.

Geis-Asteggiante L, Dhabaria A, Edwards N, Ostrand-Rosenberg S, Fenselau C.

Int J Mass Spectrom. 2015 Feb 15;378:264-269.

21.

TLR5 Ligand-Secreting T Cells Reshape the Tumor Microenvironment and Enhance Antitumor Activity.

Geng D, Kaczanowska S, Tsai A, Younger K, Ochoa A, Rapoport AP, Ostrand-Rosenberg S, Davila E.

Cancer Res. 2015 May 15;75(10):1959-1971. doi: 10.1158/0008-5472.CAN-14-2467. Epub 2015 Mar 20.

22.

Novel strategies for inhibiting PD-1 pathway-mediated immune suppression while simultaneously delivering activating signals to tumor-reactive T cells.

Ostrand-Rosenberg S, Horn LA, Alvarez JA.

Cancer Immunol Immunother. 2015 Oct;64(10):1287-93. doi: 10.1007/s00262-015-1677-5. Epub 2015 Mar 20. Review.

23.

Ubiquitinated proteins in exosomes secreted by myeloid-derived suppressor cells.

Burke MC, Oei MS, Edwards NJ, Ostrand-Rosenberg S, Fenselau C.

J Proteome Res. 2014 Dec 5;13(12):5965-72. doi: 10.1021/pr500854x. Epub 2014 Oct 29.

24.

The programmed death-1 immune-suppressive pathway: barrier to antitumor immunity.

Ostrand-Rosenberg S, Horn LA, Haile ST.

J Immunol. 2014 Oct 15;193(8):3835-41. doi: 10.4049/jimmunol.1401572. Review.

25.

Cross-talk among myeloid-derived suppressor cells, macrophages, and tumor cells impacts the inflammatory milieu of solid tumors.

Beury DW, Parker KH, Nyandjo M, Sinha P, Carter KA, Ostrand-Rosenberg S.

J Leukoc Biol. 2014 Dec;96(6):1109-18. doi: 10.1189/jlb.3A0414-210R. Epub 2014 Aug 28.

26.

HMGB1 enhances immune suppression by facilitating the differentiation and suppressive activity of myeloid-derived suppressor cells.

Parker KH, Sinha P, Horn LA, Clements VK, Yang H, Li J, Tracey KJ, Ostrand-Rosenberg S.

Cancer Res. 2014 Oct 15;74(20):5723-33. doi: 10.1158/0008-5472.CAN-13-2347. Epub 2014 Aug 27.

27.

A soluble form of CD80 enhances antitumor immunity by neutralizing programmed death ligand-1 and simultaneously providing costimulation.

Haile ST, Horn LA, Ostrand-Rosenberg S.

Cancer Immunol Res. 2014 Jul;2(7):610-5. doi: 10.1158/2326-6066.CIR-13-0204. Epub 2014 Apr 2.

28.

Exosomes from myeloid-derived suppressor cells carry biologically active proteins.

Burke M, Choksawangkarn W, Edwards N, Ostrand-Rosenberg S, Fenselau C.

J Proteome Res. 2014 Feb 7;13(2):836-43. doi: 10.1021/pr400879c. Epub 2013 Dec 13.

29.

Myeloid-derived suppressor cell function is reduced by Withaferin A, a potent and abundant component of Withania somnifera root extract.

Sinha P, Ostrand-Rosenberg S.

Cancer Immunol Immunother. 2013 Nov;62(11):1663-73. doi: 10.1007/s00262-013-1470-2. Epub 2013 Aug 27.

PMID:
23982485
30.

Soluble CD80 restores T cell activation and overcomes tumor cell programmed death ligand 1-mediated immune suppression.

Haile ST, Dalal SP, Clements V, Tamada K, Ostrand-Rosenberg S.

J Immunol. 2013 Sep 1;191(5):2829-36. doi: 10.4049/jimmunol.1202777. Epub 2013 Aug 5.

31.

Inflammation, immune suppression, and tumor progression.

Ostrand-Rosenberg S.

BMC Proc. 2013 Apr 4;7 Suppl 2:K20. doi: 10.1186/1753-6561-7-S2-K20. eCollection 2013. No abstract available.

32.

Looking to the future of cancer immunotherapy: many questions to answer and many therapeutic opportunities.

Ostrand-Rosenberg S.

Cancer Immunol Immunother. 2013 Jan;62(1):1-2. doi: 10.1007/s00262-012-1383-5. Epub 2012 Dec 20. No abstract available.

PMID:
23254777
33.

Major histocompatibility complex class II+ invariant chain negative breast cancer cells present unique peptides that activate tumor-specific T cells from breast cancer patients.

Chornoguz O, Gapeev A, O'Neill MC, Ostrand-Rosenberg S.

Mol Cell Proteomics. 2012 Nov;11(11):1457-67. doi: 10.1074/mcp.M112.019232. Epub 2012 Aug 31.

34.

IDO is a nodal pathogenic driver of lung cancer and metastasis development.

Smith C, Chang MY, Parker KH, Beury DW, DuHadaway JB, Flick HE, Boulden J, Sutanto-Ward E, Soler AP, Laury-Kleintop LD, Mandik-Nayak L, Metz R, Ostrand-Rosenberg S, Prendergast GC, Muller AJ.

Cancer Discov. 2012 Aug;2(8):722-35. doi: 10.1158/2159-8290.CD-12-0014. Epub 2012 Jul 19.

35.

Tumor-induced myeloid-derived suppressor cell function is independent of IFN-γ and IL-4Rα.

Sinha P, Parker KH, Horn L, Ostrand-Rosenberg S.

Eur J Immunol. 2012 Aug;42(8):2052-9. doi: 10.1002/eji.201142230.

36.

Regulating the suppressors: apoptosis and inflammation govern the survival of tumor-induced myeloid-derived suppressor cells (MDSC).

Ostrand-Rosenberg S, Sinha P, Chornoguz O, Ecker C.

Cancer Immunol Immunother. 2012 Aug;61(8):1319-25. doi: 10.1007/s00262-012-1269-6. Epub 2012 May 1. Review.

PMID:
22546994
37.

Coordinated regulation of myeloid cells by tumours.

Gabrilovich DI, Ostrand-Rosenberg S, Bronte V.

Nat Rev Immunol. 2012 Mar 22;12(4):253-68. doi: 10.1038/nri3175. Review.

38.

Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression.

Ostrand-Rosenberg S, Sinha P, Beury DW, Clements VK.

Semin Cancer Biol. 2012 Aug;22(4):275-81. doi: 10.1016/j.semcancer.2012.01.011. Epub 2012 Feb 1. Review.

39.

Gr-1+ CD11b+ myeloid-derived suppressor cells suppress inflammation and promote insulin sensitivity in obesity.

Xia S, Sha H, Yang L, Ji Y, Ostrand-Rosenberg S, Qi L.

J Biol Chem. 2011 Jul 1;286(26):23591-9. doi: 10.1074/jbc.M111.237123. Epub 2011 May 18.

40.

Tumor cell programmed death ligand 1-mediated T cell suppression is overcome by coexpression of CD80.

Haile ST, Bosch JJ, Agu NI, Zeender AM, Somasundaram P, Srivastava MK, Britting S, Wolf JB, Ksander BR, Ostrand-Rosenberg S.

J Immunol. 2011 Jun 15;186(12):6822-9. doi: 10.4049/jimmunol.1003682. Epub 2011 May 9.

41.

Myeloid-derived suppressor cells express the death receptor Fas and apoptose in response to T cell-expressed FasL.

Sinha P, Chornoguz O, Clements VK, Artemenko KA, Zubarev RA, Ostrand-Rosenberg S.

Blood. 2011 May 19;117(20):5381-90. doi: 10.1182/blood-2010-11-321752. Epub 2011 Mar 30.

42.

Proteomic pathway analysis reveals inflammation increases myeloid-derived suppressor cell resistance to apoptosis.

Chornoguz O, Grmai L, Sinha P, Artemenko KA, Zubarev RA, Ostrand-Rosenberg S.

Mol Cell Proteomics. 2011 Mar;10(3):M110.002980. doi: 10.1074/mcp.M110.002980. Epub 2010 Dec 29.

43.

IL-1β regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function.

Elkabets M, Ribeiro VS, Dinarello CA, Ostrand-Rosenberg S, Di Santo JP, Apte RN, Vosshenrich CA.

Eur J Immunol. 2010 Dec;40(12):3347-57. doi: 10.1002/eji.201041037.

44.

Alternative Ii-independent antigen-processing pathway in leukemic blasts involves TAP-dependent peptide loading of HLA class II complexes.

van Luijn MM, Chamuleau ME, Ressing ME, Wiertz EJ, Ostrand-Rosenberg S, Souwer Y, Zevenbergen A, Ossenkoppele GJ, van de Loosdrecht AA, van Ham SM.

Cancer Immunol Immunother. 2010 Dec;59(12):1825-38. doi: 10.1007/s00262-010-0908-z. Epub 2010 Sep 5.

45.

MHC II lung cancer vaccines prime and boost tumor-specific CD4+ T cells that cross-react with multiple histologic subtypes of nonsmall cell lung cancer cells.

Srivastava MK, Bosch JJ, Wilson AL, Edelman MJ, Ostrand-Rosenberg S.

Int J Cancer. 2010 Dec 1;127(11):2612-21. doi: 10.1002/ijc.25462.

46.

Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity.

Ostrand-Rosenberg S.

Cancer Immunol Immunother. 2010 Oct;59(10):1593-600. doi: 10.1007/s00262-010-0855-8. Epub 2010 Apr 23. Review.

47.

Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine.

Srivastava MK, Sinha P, Clements VK, Rodriguez P, Ostrand-Rosenberg S.

Cancer Res. 2010 Jan 1;70(1):68-77. doi: 10.1158/0008-5472.CAN-09-2587. Epub 2009 Dec 22.

48.

Class II-associated invariant chain peptide down-modulation enhances the immunogenicity of myeloid leukemic blasts resulting in increased CD4+ T-cell responses.

van Luijn MM, Chamuleau ME, Thompson JA, Ostrand-Rosenberg S, Westers TM, Souwer Y, Ossenkoppele GJ, van Ham SM, van de Loosdrecht AA.

Haematologica. 2010 Mar;95(3):485-93. doi: 10.3324/haematol.2009.010595. Epub 2009 Nov 10.

49.

Uveal melanoma cell-based vaccines express MHC II molecules that traffic via the endocytic and secretory pathways and activate CD8+ cytotoxic, tumor-specific T cells.

Bosch JJ, Iheagwara UK, Reid S, Srivastava MK, Wolf J, Lotem M, Ksander BR, Ostrand-Rosenberg S.

Cancer Immunol Immunother. 2010 Jan;59(1):103-12. doi: 10.1007/s00262-009-0729-0. Epub 2009 Jun 26.

50.

Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ T cells.

Hanson EM, Clements VK, Sinha P, Ilkovitch D, Ostrand-Rosenberg S.

J Immunol. 2009 Jul 15;183(2):937-44. doi: 10.4049/jimmunol.0804253. Epub 2009 Jun 24.

Supplemental Content

Loading ...
Support Center